<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6842">
    <dcterms:title><![CDATA[<strong><span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">Formulating a TMEM176B blocker in chitosan nanoparticles uncouples its paradoxical roles in innate and adaptive antitumoral immunity</span></strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[NANOPARTICULAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUITOSANO]]></dcterms:subject>
    <dcterms:subject><![CDATA[TMEM176B]]></dcterms:subject>
    <dcterms:subject><![CDATA[INFLAMASOMA]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNIDAD TUMORAL]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOENCAPSULACION]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2024]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The immunoregulatory cation channel TMEM176B plays a dual role in tumor immunity. On the one hand, TMEM176B promotes antigen cross-presentation to CD8+ T cells by regulating phagosomal pH in dendritic cells (DCs). On the other hand, it inhibits NLRP3 inflammasome activation through ionic mechanisms in DCs, monocytes and macrophages. We speculated that formulating BayK8644 in PEGylated chitosan nanoparticles (NP-PEG-BayK8644) should slowly release the compound and by that mean avoid cross-presentation inhibition (which happens with a fast 30 min kinetics) while still triggering inflammasome activation. Chitosan nanocarriers were successfully obtained, exhibiting a particle size within the range of 200 nm; they had a high positive surface charge and a 99 % encapsulation efficiency. In in vitro studies, NP-PEG-BayK8644 did not inhibit antigen cross-presentation by DCs, unlike the free compound. The NP-PEG-BayK8644 activated the inflammasome in a Tmem176b-dependent manner in DCs. We administered either empty (eNP-PEG) or NP-PEGBayK8644 to mice with established tumors. NP-PEG-BayK8644 significantly controlled tumor growth and improved mice survival compared to both eNP-PEG and free BayK8644 in melanoma and lymphoma models. This effect was associated with enhanced inflammasome activation by DCs in the tumor-draining lymph node and infiltration of the tumor by CD8+ T cells. Thus, encapsulation of BayK8644 in chitosan NPs improves the anti-tumoral properties of the compound by avoiding inhibition of antigen cross-presentation.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Victoria, Sabina</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Castro, Anal&iacute;a</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Pittini, Alvaro</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Olivera, Daniela</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Russo, Sof&iacute;a</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cebrian, Ignacio</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mombru, Alvaro W.</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Osinaga, Eduardo</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Pardo, Helena</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Segovia, Mercedes</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Hill, Marcelo</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">International Journal of Biological Macromolecules, v. 279, n&ordm; 3, 2024. -- e135327</span>]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2024]]></dcterms:date>
    <dcterms:rights><![CDATA[<div class="element-text">
<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[11 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">10.1016/j.ijbiomac.2024.135327</span>]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
